These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11713476)

  • 21. Dynamic expression of Lef/Tcf family members and beta-catenin during chick gastrulation, neurulation, and early limb development.
    Schmidt M; Patterson M; Farrell E; Münsterberg A
    Dev Dyn; 2004 Mar; 229(3):703-7. PubMed ID: 14991726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An RNA aptamer that binds to the beta-catenin interaction domain of TCF-1 protein.
    Lee SK; Park MW; Yang EG; Yu J; Jeong S
    Biochem Biophys Res Commun; 2005 Feb; 327(1):294-9. PubMed ID: 15629461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystal structure of a beta-catenin/BCL9/Tcf4 complex.
    Sampietro J; Dahlberg CL; Cho US; Hinds TR; Kimelman D; Xu W
    Mol Cell; 2006 Oct; 24(2):293-300. PubMed ID: 17052462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin.
    Labalette C; Renard CA; Neuveut C; Buendia MA; Wei Y
    Mol Cell Biol; 2004 Dec; 24(24):10689-702. PubMed ID: 15572674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters.
    Gustavson MD; Crawford HC; Fingleton B; Matrisian LM
    Mol Carcinog; 2004 Nov; 41(3):125-39. PubMed ID: 15457508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smad1, beta-catenin and Tcf4 associate in a molecular complex with the Myc promoter in dysplastic renal tissue and cooperate to control Myc transcription.
    Hu MC; Rosenblum ND
    Development; 2005 Jan; 132(1):215-25. PubMed ID: 15576399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor.
    Chesire DR; Isaacs WB
    Oncogene; 2002 Dec; 21(55):8453-69. PubMed ID: 12466965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways.
    Araki Y; Okamura S; Hussain SP; Nagashima M; He P; Shiseki M; Miura K; Harris CC
    Cancer Res; 2003 Feb; 63(3):728-34. PubMed ID: 12566320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin.
    Huber AH; Weis WI
    Cell; 2001 May; 105(3):391-402. PubMed ID: 11348595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Galectin-3, a novel binding partner of beta-catenin.
    Shimura T; Takenaka Y; Tsutsumi S; Hogan V; Kikuchi A; Raz A
    Cancer Res; 2004 Sep; 64(18):6363-7. PubMed ID: 15374939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling.
    Park CH; Hahm ER; Park S; Kim HK; Yang CH
    FEBS Lett; 2005 May; 579(13):2965-71. PubMed ID: 15893313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers.
    Vécsey-Semjén B; Becker KF; Sinski A; Blennow E; Vietor I; Zatloukal K; Beug H; Wagner E; Huber LA
    Oncogene; 2002 Jul; 21(30):4646-62. PubMed ID: 12096341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis.
    Takahashi M; Fujita M; Furukawa Y; Hamamoto R; Shimokawa T; Miwa N; Ogawa M; Nakamura Y
    Cancer Res; 2002 Oct; 62(20):5651-6. PubMed ID: 12384519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour).
    Tejpar S; Li C; Yu C; Poon R; Denys H; Sciot R; Van Cutsem E; Cassiman JJ; Alman BA
    Br J Cancer; 2001 Jul; 85(1):98-101. PubMed ID: 11437409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the Tcf4 G13ANDE17 binding site to selectively disrupt β-catenin/T-cell factor protein-protein interactions.
    Huang Z; Zhang M; Burton SD; Katsakhyan LN; Ji H
    ACS Chem Biol; 2014 Jan; 9(1):193-201. PubMed ID: 24191653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A yeast model system for functional analysis of beta-catenin signaling.
    Lee MS; D'Amour KA; Papkoff J
    J Cell Biol; 2002 Sep; 158(6):1067-78. PubMed ID: 12235124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic peptide array-based delineation of the differential beta-catenin interaction with Tcf4, E-cadherin, and adenomatous polyposis coli.
    Gail R; Frank R; Wittinghofer A
    J Biol Chem; 2005 Feb; 280(8):7107-17. PubMed ID: 15591320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Membrane-anchored plakoglobins have multiple mechanisms of action in Wnt signaling.
    Klymkowsky MW; Williams BO; Barish GD; Varmus HE; Vourgourakis YE
    Mol Biol Cell; 1999 Oct; 10(10):3151-69. PubMed ID: 10512857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. beta-catenin: molecular plasticity and drug design.
    Daniels DL; Eklof Spink K; Weis WI
    Trends Biochem Sci; 2001 Nov; 26(11):672-8. PubMed ID: 11701326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiological regulation of [beta]-catenin stability by Tcf3 and CK1epsilon.
    Lee E; Salic A; Kirschner MW
    J Cell Biol; 2001 Sep; 154(5):983-93. PubMed ID: 11524435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.